The stock's fall snapped a two-day winning streak.

This was the stock's third consecutive day of losses.

Tron: Catalyst review: "Disc slinging is a thrill in this gorgeous rendition of the series, but I'm let down by a time-loop story that falls flat" Reviews By Max Williams published June 17, 2025 ...

Revenue Growth: Catalyst Pharmaceuticals's remarkable performance in 3 months is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 43.56%.

Discover how advanced catalyst materials enable efficient CO2 hydrogenation, converting greenhouse gases into valuable fuels like methanol and hydrocarbons.

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 11.7% during the 4th quarter ...

Grammarly has raised $1 billion in non-dilutive financing from General Catalyst to expand its artificial intelligence (AI) offerings, aiming to grow into a comprehensive productivity platform, the ...

Grammarly has secured a $1 billion commitment from General Catalyst. The 16-year-old writing assistant startup will use the new funds for its sales and marketing efforts, freeing up existing ...

The new ruthenium core-shell catalyst sets a benchmark in hydrogen production, combining high efficiency with reduced precious metal usage for sustainability.

Tomorrows’ Rx is leading the charge in modernizing prescription medication access, providing a seamless, efficient, and confidential way for individuals to obtain necessary treatments without ...

StockNews.com upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) from a buy rating to a strong-buy rating in a research note issued to investors on Friday. Several other ...